Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Approval Alert | Perioperative Nivolumab/Chemotherapy in Resectable NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
4
3 Things You Should Know About Frontline TROP2-Targeting Antibody-Drug Conjugate/Immune Checkpoint Inhibitor Combinations to Treat Advanced Triple-Negative Breast Cancer
5
